1. Safety Testing of Ovaprene: an Investigational Non-Hormonal Monthly Vaginal Contraceptive
- Author
-
Mauck, Christine, Thurman, Andrea, Jensen, Jeffrey T, Schreiber, Courtney A, Baker, Jeff, Hou, Melody Y, Chavoustie, Steven, Dart, Clint, Wu, Hongsheng, Ravel, Jacques, Gajer, Pawel, Herold, Betsy C, Jacot, Terry, Zack, Nadene, Hatheway, Jessica, and Friend, Dave
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Infectious Diseases ,Patient Safety ,Clinical Research ,Contraception/Reproduction ,Good Health and Well Being ,Contraception ,Ovaprene ,contraceptive ,vaginal ,Paediatrics and Reproductive Medicine ,Public Health and Health Services ,Obstetrics & Reproductive Medicine ,Clinical sciences ,Reproductive medicine ,Health services and systems - Abstract
ObjectiveEvaluate safety of Ovaprene, an investigational non-hormonal vaginal contraceptive designed for monthly use.Study designOpen-label, multicenter study enrolling heterosexually-active women with previous permanent contraception who underwent assessments during five menstrual cycles: baseline postcoital test cycle, diaphragm postcoital test cycle, Ovaprene safety cycle, and two Ovaprene postcoital test cycles. Safety outcomes included treatment emergent adverse events (TEAEs), systemic laboratory findings, pelvic examinations, colposcopies, Nugent scores, determination of community state types of vaginal microbiota, and anti-Escherichia coli activity and inflammatory markers in cervicovaginal fluids.ResultsWe enrolled 38 participants. Of these, 33 used Ovaprene and completed 77 Ovaprene cycles. The most common product-related urogenital TEAEs were bacterial vaginosis (BV) and vaginal odor. The frequency of transitioning from Lactobacillus-dominated community state type to community state type IV (not Lactobacillus-dominated) was similar before Ovaprene use and afterwards. Mean Nugent scores were
- Published
- 2024